Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0775758
Funder
Australian Research Council
Funding Amount
$587,000.00
Summary
A Mass Spectrometry and Proteomics Facility. This facility will support a large group of nationally and internationally recognised scientists working on a range of projects in the National Interest: the role of apoptosis in normal and diseased cells, mitochondrial biogenesis and genetic diseases resulting from defects in mitochondrial function, malarial vaccine and drug development, plant biotehnology, design and synthesis of drugs, DNA-anticancer drug interactions and biomarker discovery. By su ....A Mass Spectrometry and Proteomics Facility. This facility will support a large group of nationally and internationally recognised scientists working on a range of projects in the National Interest: the role of apoptosis in normal and diseased cells, mitochondrial biogenesis and genetic diseases resulting from defects in mitochondrial function, malarial vaccine and drug development, plant biotehnology, design and synthesis of drugs, DNA-anticancer drug interactions and biomarker discovery. By supporting this wide range of well funded researh, the mass spectrometry facility will support the emerging Biotechnology sector and National Research Priorities.Read moreRead less
Blood flow routes in muscle. Ageing well, ageing productively. The Australian population is ageing. The proportion of the population over the age of 65 is expected to greatly increase, reaching 22% by the year 2030. The prevalence of type 2 diabetes in this older population is thought to be ~20%, compared to ~6% in younger populations. An initial cause of type 2 diabetes may be microvascular dysfunction brought on by physical inactivity. Therefore this project addresses the concepts of microvasc ....Blood flow routes in muscle. Ageing well, ageing productively. The Australian population is ageing. The proportion of the population over the age of 65 is expected to greatly increase, reaching 22% by the year 2030. The prevalence of type 2 diabetes in this older population is thought to be ~20%, compared to ~6% in younger populations. An initial cause of type 2 diabetes may be microvascular dysfunction brought on by physical inactivity. Therefore this project addresses the concepts of microvascular function and microvascular fitness by using the latest technology to map blood flow routes in muscle under a number of relevant situations. Read moreRead less
Microdialysis for monitoring changes in microvascular flow patterns in muscle. Microdialysis is a technique for sampling interstitial fluid. Factors altering vascular delivery and removal of nutrients and hormones can affect muscle metabolism by altering exchange with the interstitium. This project focuses on microdialysis for assessing the impact of microvascular blood flow patterns on skeletal muscle metabolism and contractility. The aim is to develop and refine the technology, including equat ....Microdialysis for monitoring changes in microvascular flow patterns in muscle. Microdialysis is a technique for sampling interstitial fluid. Factors altering vascular delivery and removal of nutrients and hormones can affect muscle metabolism by altering exchange with the interstitium. This project focuses on microdialysis for assessing the impact of microvascular blood flow patterns on skeletal muscle metabolism and contractility. The aim is to develop and refine the technology, including equations, specifically for monitoring the nutritive fraction of blood flow in muscle by agents and factors relating to health and disease. This technique could be used for screening drugs in the treatment of diseases such as type 2 diabetes and related conditions.Read moreRead less
Novel biodiagnostic platforms for human metabolites. The innovative biosensor technologies developed in this project will be utilised at first by Australian athletes, enabling them to better monitor physiological conditions during training and thereby help maintain international competitiveness. Real-time sensing of lactate and other metabolites in athletes using advanced biomaterials coupled to frontier telemetry protocols for remote sensing will be extendable to bio-diagnostic needs in human h ....Novel biodiagnostic platforms for human metabolites. The innovative biosensor technologies developed in this project will be utilised at first by Australian athletes, enabling them to better monitor physiological conditions during training and thereby help maintain international competitiveness. Real-time sensing of lactate and other metabolites in athletes using advanced biomaterials coupled to frontier telemetry protocols for remote sensing will be extendable to bio-diagnostic needs in human health care and have significant social and economic benefits. Australia's international position in the application of interfacial science and nanomaterials for outcomes in biomedical engineering will be strengthened. Read moreRead less
Ultrasound in muscle vascular research, and gene therapy. This project focuses on ultrasound and microbubbles for the imaging of microvascular blood flow patterns in skeletal muscle and as a modality for drug delivery. The aim is to develop and refine technology specifically for (i) assessment of muscle microvascular flow in health and disease, and for (ii) delivery of state-of-the art gene constructs to endothelial cells that control blood flow in the muscle microvasculature. We anticipate impr ....Ultrasound in muscle vascular research, and gene therapy. This project focuses on ultrasound and microbubbles for the imaging of microvascular blood flow patterns in skeletal muscle and as a modality for drug delivery. The aim is to develop and refine technology specifically for (i) assessment of muscle microvascular flow in health and disease, and for (ii) delivery of state-of-the art gene constructs to endothelial cells that control blood flow in the muscle microvasculature. We anticipate improved technology for early diagnosis of impairment in microvascular flow relevant to muscle insulin resistance and novel therapeutics that improve muscle microvascular blood flow applicable to the treatment of diabetes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0452281
Funder
Australian Research Council
Funding Amount
$102,900.00
Summary
Muscle Vascular Research and Gene Therapy Using Ultrasound. We seek funds to set up a national facility for ultrasound in muscle vascular research and gene therapy. Ultrasound with microbubbles will be used for the imaging of muscle microvascular blood flow and as a delivery modality for gene constructs to endothelial cells that control blood flow. The technology has application to (i) the assessment and therapeutic treatment of impaired microvascular function as in diabetics; (ii) the assessmen ....Muscle Vascular Research and Gene Therapy Using Ultrasound. We seek funds to set up a national facility for ultrasound in muscle vascular research and gene therapy. Ultrasound with microbubbles will be used for the imaging of muscle microvascular blood flow and as a delivery modality for gene constructs to endothelial cells that control blood flow. The technology has application to (i) the assessment and therapeutic treatment of impaired microvascular function as in diabetics; (ii) the assessment of adaptation to physical training and (iii) the development of therapeutic agents used to treat diabetes. We anticipate improved technology that is fully characterized and novel therapeutics that improve microvascular blood flow.Read moreRead less
Defining targets and generating tools/therapeutic agents for prevention, diagnosis and therapy of atherothrombosis. Atherosclerosis and its complications such as myocardial infarction and stroke are a major cause of death and disability in Australia and worldwide. The proposed research program investigates new therapeutic targets and concepts (e.g. targeting of stem cells) to treat atherosclerosis and aims to develop new therapeutic agents using modern biotechnological methods. The project furth ....Defining targets and generating tools/therapeutic agents for prevention, diagnosis and therapy of atherothrombosis. Atherosclerosis and its complications such as myocardial infarction and stroke are a major cause of death and disability in Australia and worldwide. The proposed research program investigates new therapeutic targets and concepts (e.g. targeting of stem cells) to treat atherosclerosis and aims to develop new therapeutic agents using modern biotechnological methods. The project further aims to develop nanoparticle-based diagnostic tools to identify and preventatively treat atherosclerotic plaques that are prone to cause myocardial infarction. The expected outcome will provide direct benefit to patients and create new economic opportunities in Australian bio-/nanotechnology.Read moreRead less
Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. ....Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. It will promote capacity of Australia for manufacturing global biomaterial products for tissue engineering. We will also develop in-situ imaging analytical protocols for the rapid analysis of broad arrays of functional molecules, with significant bearing on BioMEMS design to develop methods for diagnosis of fatal diseases.Read moreRead less
Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management ....Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management of those at risk of heart attack, the single biggest contributor to healthcare costs in Australia. We further aim to adapt this technology to enable "point-of-care" assays that would help medical practitioners, especially in rural areas, to make informed diagnoses immediately.Read moreRead less
Long Chain Omega-3 Polyunsaturated Fatty Acids and Heart Health in Humans. The primary aims of the project is to assess the effect of DHA rich tuna oil on cholesterol carrying lipoproteins and to determine a quicker method in assessing someone's omega-3 status. The expected outcomes include the determination of: 1) the most appropriate blood sample and a rapid test and for evaluating the omega-3 status; 2) the minimum dose of tuna oil required which will not only improve a person's omega-3 statu ....Long Chain Omega-3 Polyunsaturated Fatty Acids and Heart Health in Humans. The primary aims of the project is to assess the effect of DHA rich tuna oil on cholesterol carrying lipoproteins and to determine a quicker method in assessing someone's omega-3 status. The expected outcomes include the determination of: 1) the most appropriate blood sample and a rapid test and for evaluating the omega-3 status; 2) the minimum dose of tuna oil required which will not only improve a person's omega-3 status but also improve their plasma lipid profile and hence reduce their overall risk for cardiovascular disease (CVD); and 3) the use of the Omega-3 Index by medical practitioners. The significance is the increased knowledge of the health benefits of DHA rich tuna oil and that a new CVD risk marker will be generally accepted.Read moreRead less